Nicholas C K Valerie

6PUBLICATIONS
13CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsMolecular targetsProteins and peptidesPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 06, 2024
Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM.

Nicholas C K Valerie, Kumar Sanjiv, Oliver Mortusewicz

|Nov 03, 2019
Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Brent D G Page, Nicholas C K Valerie, Roni H G Wright

|Jan 19, 2018
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Brent D G Page, Nicholas C K Valerie, Roni H G Wright

|Sep 02, 2017
Correction to Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.

Sabin Llona-Minguez, Andreas Höglund, Artin Ghassemian

|May 17, 2017
Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.

Sabin Llona-Minguez, Andreas Höglund, Artin Ghassemian

|Jan 10, 2017
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Nikolas Herold, Sean G Rudd, Linda Ljungblad

Pageof 1

Frequent Collaborators

4 joint publications

Sabin Llona-Minguez

2 joint publications

Sean G Rudd

1 joint publications

Nikolas Herold

1 joint publications

Torsten Schaller